Abstract
Major depressive disorder (MDD) and other psychiatric diseases can greatly benefit from objective decision support in diagnosis and therapy. Machine learning approaches based on electroencephalography (EEG) have the potential to serve as low-cost decision support systems. Despite the successful demonstration of this approach, contradictory findings regarding the diagnostic value of those biomarkers hamper their deployment in a clinical setting. Therefore, the reproducibility and robustness of these biomarkers needs to be established first. We employ a multiverse analysis to systematically investigate variations in five data processing steps, which may be one source of contradictory findings. These steps are normalization, time-series segment length, biomarker from the alpha band, aggregation, and classification algorithm. For replicability of our results, we utilize two publicly available EEG data sets with eyes-closed resting-state data containing 16/19 MDD patients and 14/14 healthy control subjects. The diagnostic classifiers range from chance level up to 85%, dependent on dataset and combination of processing steps. We find a large influence of choice of processing steps and their combinations. However, only the biomarker has an overall significant effect on both datasets. We find one biomarker candidate that has shown a robust and reproducible high performance for MDD diagnostic support, the relative centroid frequency. Overall, the replicability of our findings with the two datasets is rather inconsistent. This study is a showcase for the advantages of employing a multiverse approach in EEG data analysis and advocates for larger, well-curated data sets to further neuroscience research that can be translated to clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by grant KK5207801BM0 to A. Reichenbach from the German Federal Ministry for Economic Affairs and Climate Action.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Two publicly available datasets were used for this study: 1: Mumtaz W. MDD Patients and Healthy Controls EEG Data (New). Published online 2016:903228416 Bytes. doi:10.6084/M9.FIGSHARE.4244171.V2 2: Cai H, Gao Y, Sun S, et al. MODMA dataset: a Multi-modal Open Dataset for Mental-disorder Analysis. Sci Data. 2022;9(1):178. doi:10.1038/s41597-022-01211-x
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript or are available upon reasonable request to the authors.
